Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Francesca Bruce
New regulations in Canada could mean companies are required to notify the country's regulator more quickly about foreign-risk communications and conduct new post-marketing safety tests.
New regulations in Canada could mean companies are required to notify the regulator more quickly about foreign risk communications and conduct new post-marketing safety tests.
New oncology drugs forming new treatment combinations will face a tough ride through England’s influential health technology appraisal body, NICE.
Manufacturers selling oncology drugs in Canada could soon face group price negotiations and performance-based reimbursement agreements as authorities in the country plan to improve access to oncology drugs.
Brazil could soon be manufacturing its own generic version of Gilead’s Sovaldi if opposition to the company’s patent application is upheld by the patent office.
Pharmaceutical companies with maturing portfolios need to understand tendering if they want to prevent international price erosion.